{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:38:07Z","timestamp":1769121487736,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pcl.2023.05.008","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T01:51:16Z","timestamp":1688608276000},"page":"951-961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Shedding New Light"],"prefix":"10.1016","volume":"70","author":[{"given":"Nadia","family":"Merchant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Dauber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pcl.2023.05.008_bib1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-1010","article-title":"Health supervision for people with achondroplasia","volume":"145","author":"Hoover-Fong","year":"2020","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.pcl.2023.05.008_bib2","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/ajmg.a.61787","article-title":"Birth prevalence of achondroplasia: a systematic literature review and meta-analysis","volume":"182","author":"Foreman","year":"2020","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.pcl.2023.05.008_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/TACG.S51485","article-title":"Optimal management of complications associated with achondroplasia","volume":"7","author":"Ireland","year":"2014","journal-title":"Appl Clin Genet"},{"issue":"9582","key":"10.1016\/j.pcl.2023.05.008_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0140-6736(07)61090-3","article-title":"Achondroplasia","volume":"370","author":"Horton","year":"2007","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.008_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1186\/s13023-021-02141-4","article-title":"Growth in achondroplasia including stature, weight, weight-for-height and head circumference from CLARITY: achondroplasia natural history study-a multi-center retrospective cohort study of achondroplasia in the US","volume":"16","author":"Hoover-Fong","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"10.1016\/j.pcl.2023.05.008_bib6","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ajmg.a.61366","article-title":"Nosology and classification of genetic skeletal disorders: 2019 revision","volume":"179","author":"Mortier","year":"2019","journal-title":"Am J Med Genet"},{"issue":"9\u201310","key":"10.1016\/j.pcl.2023.05.008_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000520812","article-title":"Evolution and future of growth plate therapeutics","volume":"94","author":"Allen","year":"2021","journal-title":"Horm Res Paediatr"},{"issue":"12","key":"10.1016\/j.pcl.2023.05.008_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrendo.2015.165","article-title":"Short and tall stature: a new paradigm emerges","volume":"11","author":"Baron","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pcl.2023.05.008_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15369","article-title":"Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP","author":"Breinholt","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.pcl.2023.05.008_bib10","doi-asserted-by":"crossref","first-page":"e81569","DOI":"10.1371\/journal.pone.0081569","article-title":"Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia","volume":"8","author":"Matsushita","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pcl.2023.05.008_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1399-0004.2008.01123.x","article-title":"Clinical and molecular diagnosis of the skeletal dysplasias associated with mutations in the gene encoding Fibroblast Growth Factor Receptor 3 (FGFR3) in Portugal","volume":"75","author":"Almeida","year":"2009","journal-title":"Clin Genet"},{"key":"10.1016\/j.pcl.2023.05.008_bib12","unstructured":"Bober MB, Bellus GA, Nikkel SM, et al. Hypochondroplasia. 1999 Jul 15 [Updated 2020 May 7]. In: Adam MP, Mirzaa GM, Pagon RA, et al. editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1477\/."},{"key":"10.1016\/j.pcl.2023.05.008_bib13","unstructured":"French T, Savarirayan R. Thanatophoric Dysplasia. 2004 May 21 [Updated 2023 May 18]. In: Adam MP, Mirzaa GM, Pagon RA, et al. editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1366\/."},{"key":"10.1016\/j.pcl.2023.05.008_bib14","first-page":"9940063","article-title":"Prenatal diagnosis of skeletal dysplasia and review of the literature","volume":"2021","author":"Jimah","year":"2021","journal-title":"Case Rep Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.pcl.2023.05.008_bib15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1086\/302275","article-title":"A\u00a0novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene","volume":"64","author":"Tavormina","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"21","key":"10.1016\/j.pcl.2023.05.008_bib16","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1002\/ajmg.a.31919","article-title":"Mortality in achondroplasia study: a 42-year follow-up","volume":"143A","author":"Wynn","year":"2007","journal-title":"Am J Med Genet"},{"issue":"3","key":"10.1016\/j.pcl.2023.05.008_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41574-021-00595-x","article-title":"International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia","volume":"18","author":"Savarirayan","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.008_bib18","first-page":"3","article-title":"Limb lengthening history, evolution, complications and current concepts","volume":"21","author":"Hosny","year":"2020","journal-title":"J\u00a0Orthop Trauma"},{"issue":"Suppl 1","key":"10.1016\/j.pcl.2023.05.008_bib19","first-page":"123","article-title":"Growth hormone treatment for achondroplasia","volume":"16","author":"Yorifuji","year":"2018","journal-title":"Pediatr Endocrinol Rev"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.008_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000446958","article-title":"Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis","volume":"86","author":"Miccoli","year":"2016","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.008_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/jpet.114.218560","article-title":"Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism","volume":"353","author":"Wendt","year":"2015","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.pcl.2023.05.008_bib22","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia","volume":"91","author":"Lorget","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.008_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.pcl.2023.05.008_bib24","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/s41436-021-01287-7","article-title":"Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study","volume":"23","author":"Savarirayan","year":"2021","journal-title":"Genet Med"},{"issue":"10252","key":"10.1016\/j.pcl.2023.05.008_bib25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.pcl.2023.05.008_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/jpet.119.258251","article-title":"TransCon CNP, a sustained-release C-type natriuretic peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with fibroblast growth factor receptor 3-related skeletal dysplasias","volume":"370","author":"Breinholt","year":"2019","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.pcl.2023.05.008_bib27","unstructured":"Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05246033?cond=achondroplasia&draw=2&rank=2. Accessed June 25, 2023."},{"key":"10.1016\/j.pcl.2023.05.008_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221084848","article-title":"Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies","volume":"14","author":"Savarirayan","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.pcl.2023.05.008_bib29","unstructured":"Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma#:\u223c:text=On%20May%2028%2C%202021%2C%20theF. Accessed June 25, 2023."},{"issue":"5","key":"10.1016\/j.pcl.2023.05.008_bib30","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI83926","article-title":"Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model","volume":"126","author":"Komla-Ebri","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pcl.2023.05.008_bib31","unstructured":"Available at: https:\/\/investor.bridgebio.com\/news-releases\/news-release-details\/bridgebio-pharma-announces-positive-interim-results-phase-2. Accessed June 25, 2023."},{"issue":"203","key":"10.1016\/j.pcl.2023.05.008_bib32","doi-asserted-by":"crossref","first-page":"203ra124","DOI":"10.1126\/scitranslmed.3006247","article-title":"Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice","volume":"5","author":"Garcia","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pcl.2023.05.008_bib33","unstructured":"Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04638153. Accessed June 25, 2023."},{"issue":"2","key":"10.1016\/j.pcl.2023.05.008_bib34","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1210\/en.2014-1914","article-title":"Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene","volume":"156","author":"Matsushita","year":"2015","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.008_bib35","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1038\/s41598-017-07044-8","article-title":"Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia","volume":"7","author":"Matsushita","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.pcl.2023.05.008_bib36","doi-asserted-by":"crossref","first-page":"e0229639","DOI":"10.1371\/journal.pone.0229639","article-title":"Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia","volume":"15","author":"Kitoh","year":"2020","journal-title":"PLoS One"},{"issue":"592","key":"10.1016\/j.pcl.2023.05.008_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4226","article-title":"An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice","volume":"13","author":"Kimura","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pcl.2023.05.008_bib38","unstructured":"Available at: https:\/\/www.ribomic.com\/eng\/pipeline\/rbm007.php. Accessed June 25, 2023."},{"issue":"11","key":"10.1016\/j.pcl.2023.05.008_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115573","article-title":"Advantages and disadvantages of different treatment methods in achondroplasia: a review","volume":"22","author":"Wrobel","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pcl.2023.05.008_bib40","unstructured":"Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04219007?term=selected+genetic+causes+of+short+stature&draw=2&rank=1. Accessed June 25, 2023."}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395523000998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395523000998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:26:50Z","timestamp":1758475610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395523000998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0031395523000998"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2023.05.008","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shedding New Light","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2023.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}